Aratana Therapeutics Inc (PETX) Expected to Announce Quarterly Sales of $6.98 Million

Equities research analysts expect that Aratana Therapeutics Inc (NASDAQ:PETX) will report sales of $6.98 million for the current quarter, Zacks reports. Three analysts have made estimates for Aratana Therapeutics’ earnings. The highest sales estimate is $7.80 million and the lowest is $5.53 million. Aratana Therapeutics posted sales of $4.04 million in the same quarter last year, which suggests a positive year over year growth rate of 72.8%. The firm is expected to report its next earnings report on Thursday, May 2nd.

According to Zacks, analysts expect that Aratana Therapeutics will report full year sales of $35.12 million for the current fiscal year, with estimates ranging from $26.66 million to $39.40 million. For the next fiscal year, analysts forecast that the business will post sales of $72.60 million, with estimates ranging from $56.71 million to $91.00 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Aratana Therapeutics.

Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings data on Tuesday, March 12th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.06). Aratana Therapeutics had a negative net margin of 41.57% and a negative return on equity of 14.78%. The business had revenue of $4.91 million for the quarter, compared to the consensus estimate of $6.53 million.

Several research firms have commented on PETX. Zacks Investment Research lowered shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, March 14th. TheStreet lowered shares of Aratana Therapeutics from a “c-” rating to a “d+” rating in a research report on Monday, March 4th. William Blair lowered shares of Aratana Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.14 price objective for the company. in a research report on Thursday, January 24th. Stifel Nicolaus lowered shares of Aratana Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the company from $8.00 to $5.00 in a research report on Friday, January 11th. Finally, BidaskClub lowered shares of Aratana Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 11th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $6.41.

Institutional investors and hedge funds have recently made changes to their positions in the company. Truvestments Capital LLC purchased a new stake in shares of Aratana Therapeutics in the first quarter valued at $25,000. Toth Financial Advisory Corp purchased a new stake in shares of Aratana Therapeutics in the first quarter valued at $30,000. Adams Asset Advisors LLC purchased a new stake in shares of Aratana Therapeutics in the first quarter valued at $36,000. Raymond James & Associates purchased a new stake in shares of Aratana Therapeutics in the fourth quarter valued at $65,000. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in shares of Aratana Therapeutics in the fourth quarter valued at $88,000. 68.14% of the stock is currently owned by institutional investors and hedge funds.

PETX stock opened at $3.60 on Tuesday. Aratana Therapeutics has a 52 week low of $3.30 and a 52 week high of $7.16. The firm has a market cap of $185.60 million, a price-to-earnings ratio of -11.25 and a beta of 1.36.

About Aratana Therapeutics

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States.

Featured Story: Trading Penny Stocks

Get a free copy of the Zacks research report on Aratana Therapeutics (PETX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit